Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2023
2022
2021
2020
2019
2018
2017
Nov 16, 2023
Mabwell Announces the Appointment of Dr. Hai Wu as the President of R&D
➞
Oct 30, 2023
Mabwell Established a Licensing and Commercialization Agreement of Adalimumab Biosimilar for Argentina Market
➞
Oct 25, 2023
Good Safety Profile and Antitumor Activity: Oral Presentation of Mabwell’s 9MW2821 at 2023 ESMO
➞
Oct 23, 2023
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs
➞
Sep 27, 2023
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor
➞
Sep 26, 2023
Mabwell Partners with Legrand to Market Denosumab Biosimilars in Colombia and Ecuador
➞
Sep 22, 2023
FDA Grants Fast Track Designation to 9MW3011
➞
Sep 06, 2023
Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration to Accelerate Global Layout of Innovative Biologics
➞
Sep 05, 2023
Mabwell Announces the First Patient Dosed in the Clinical Studies of 2 Novel ADCs
➞
Aug 28, 2023
Mabwell Partners with UNILAB to Market its Adalimumab Biosimilar in the Philippines
➞
1
2
3
4
下一页